14 results
Ticagrelor, at steady state (i.e. after 30 days), will be associated to an improved endothelial function as compared to clopidogrel or prasugrel.
The primary objective of this study is to demonstrate non-inferiority by pharmacodynamic (PD) analysis of the prasugrel 5-mg maintenance dose (MD) in aspirin-treated subjects <60 kg with stable coronary artery disease (CAD) versus the…
The primary objective of this study is to demonstrate non-inferiority by pharmacodynamic (PD) analysis of the prasugrel 5-mg maintenance dose (MD) in aspirin-treated subjects >=75 years of age with stable coronary artery disease (CAD) versus…
The objective of the study is to quantify the effect of pregabaline and lacosamide on oxycodone-induced respiratory depression.
Study Rationale and ObjectivesThe objective of the study is to determine the efficacy and safety of lacosamide, a sodium channel blocker, in patients with pain due to SCN9A-associated SFN. The proposed study plans to recruit patients with clinically…
To evaluate safety of 3-months versus standard 12-months of DAPT
To assess the efficacy, safety and cost-effectiveness of the CYP2C19 genotype guided antiplatelet treatment strategy, using clopidogrel or prasugrel/ticagrelor.
A better understanding on the individual response to different albuminuria lowering drugs and a better understanding why these drugs, of which some are developed for another indication, may help to tailor optimal therapy. Therefore in this study…
To assess the safety, efficacy and net clinical benefit of clopidogrel versus the new antiplatelet drugs i.e. ticagrelor and prasugrel in patients older than 70 years.
To determine if ticagrelor at treatment steady state will be associated to an improved microvascular function as compared to prasugrel in revascularized STEMI patients.
To evaluate the effect of baricitinib 4-mg QD and background standard-of-care therapy compared with placebo and background standard-of-care therapy on SLE disease activity.
PrimaryTo evaluate the long-term safety and tolerability of baricitinib in patients with SLE.
The primary objective of this study is to assess the feasibility and safety of a single antiplatelet strategy with prasugrel or ticagrelor prior to, during and after PCI with a new generation drug-eluting in non-ST-elevation acute coronary syndrome…
The primary objective is to test the hypothesis that baricitinib high dose level in combination with topical corticosteroids (TCS) or baricitinib medium dose level in combination with TCS is superior to placebo in combination with TCS in the…